Company intelligence / Profile preview

Pharming Group

Leiden, South Holland, Netherlandspharming.com ↗
Ownership
Public · PHAR
Employees
~415
Development stage
Other
01

Overview

Pharming Group is a global biopharmaceutical company commercializing two main products. RUCONEST® is an approved recombinant human C1 esterase inhibitor for acute hereditary angioedema, marketed in the US, EU, and other regions. Joenja® (leniolisib) is the first and only FDA-approved treatment for APDS, launched in the US in 2023 with ongoing expansion into additional markets and pediatric indications. The company continues to expand its pipeline into related rare diseases and primary immunodeficiencies.

Therapeutic areas
Immunology
Modalities
Recombinant proteinSmall moleculeBiologicGene therapy
Industry
Biotech
02

Drug pipeline

5 assets

conestat alfa

Approved

4 more assets in the full pipeline.

03

Partnerships

Swedish Orphan Biovitrum – EU distribution of RuconestSantarus – North America partnership for RuconestShanghai Institute for Pharmaceutical Industry/Sinopharm – joint global development of recombinant proteins including rhFVIII for hemophilia A
04

Financials

Market cap
$870.6M
Total revenue
$376.1M
Enterprise value
$795.5M

Beyond the preview

Go deeper on Pharming Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pharming Group.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call